There’s a new team occupying the executive suite at Merck. And they’ve got a new game plan
Now that Rob Davis and his newly recruited crew of C-suite execs are about to take full control of Merck, it’s time to update the strategy manual and fire up some enthusiasm for the pharma giant with a refreshed game plan.
And who better to get that message across than sell-side analysts on Wall Street?
Davis — who technically has to wait until July 1 to assume the title — and new CFO Caroline Litchfield had a virtual sit-down with a group of analysts this week to make sure they knew that they were raring to do things…somewhat differently. And that includes using a financial windfall and streamlining drive to allow the BD side to up their game gambling while demonstrating a willingness to tear down the digital curtain thrown around Phase I and spotlight early-stage research.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 125,100+ biopharma pros reading Endpoints daily — and it's free.